CLPP and neoplasm: Subjecting imipridones and TR-compounds to analysis using the central nervous system multi-parameter optimization (CNS-MPO) computation tool,84 predicted all ClpP-agonists as good candidates to cross the BBB and enter the brain/tumor when delivered systemically (Table 3).